Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (Germany)
The Regents of the University of Michigan (USA)
Iowa State University Research Foundation, Inc. (USA)
Inventor
Zischka, Hans
Dispirito, Alan Angelo
Semrau, Jeremy David
Abstract
The present invention relates to a methanobactin reducing Fe3+ ions to Fe2+ ions for use in medicine and a pharmaceutical composition comprising said methanobactin as well as to a process for reducing Fe3+ ions to Fe2+ ions ex vivo.
Methods for performing non-invasive thrombolysis with ultrasound using, in some embodiments, one or more ultrasound transducers to focus or place a high intensity ultrasound beam onto a blood clot (thrombus) or other vascular inclusion or occlusion (e.g., clot in the dialysis graft, deep vein thrombosis, superficial vein thrombosis, arterial embolus, bypass graft thrombosis or embolization, pulmonary embolus) which would be ablated (eroded, mechanically fractionated, liquefied, or dissolved) by ultrasound energy. The process can employ one or more mechanisms, such as of cavitational, sonochemical, mechanical fractionation, or thermal processes depending on the acoustic parameters selected. This general process, including the examples of application set forth herein, is henceforth referred to as “Thrombolysis.”
A61B 17/22 - Surgical instruments, devices or methods, e.g. tourniquets for removing obstructions in blood vessels, not otherwise provided for
A61B 17/225 - Surgical instruments, devices or methods, e.g. tourniquets for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves
A61M 37/00 - Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
3.
Automated Framework For Monitoring Opt-Out Settings
A computer-implemented method is presented for detecting non-compliance with an opt-out decision of a user. The method includes: identifying select statements of a privacy policy for an online tracking entity by analyzing webpages associated with the online tracking entity, where the select statements specify data practices in response to an opt-out decision; detecting transfer of cookies from a web browser to a server, where the cookies are transferred after an opt-out decision by the given user and the server is associated with the given online tracking entity; analyzing content of the detected cookies in relation to the select statements of the privacy policy; and notifying the given user of a violation of the privacy policy in response to determining an inconsistency between the content of the detected cookies and the select statements of the privacy policy.
An ankle-foot orthosis includes a leg portion and a foot portion. The foot portion is biased toward an equilibrium angle with respect to the leg portion, and the equilibrium angle is adjustable to accommodate different users' natural stance. An adjustable leg stay permits fitting the orthosis to multiple different users, and the orthosis can be fitted to either leg of a user with only a foot plate change. A variable stiffness spring and cam system modulate ankle joint stiffness according to a pre-defined cam profile. The contact point of the cam system is forward of the user's heel and thus closer to the ankle joint, enabling reduced-size components. Two rotational degrees of freedom are provided in plantarflexion/dorsiflexion and inversion/eversion.
A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
A gear set comprising an input shaft, an output shaft, a gear; and a friction pad. In a first configuration, the gear set has a first gear ratio for the input shaft rotational speed to the output shaft rotational speed equal to N:1, where N is not equal to 1. In the first configuration, the gear rotates relative to the friction pad. In a second configuration, the gear set has a gear ratio for the input shaft rotational speed to the output shaft rotational speed equal to 1:1, wherein the friction pad prevents rotation of the gear relative to the friction pad.
F16H 3/10 - Toothed gearings for conveying rotary motion with variable gear ratio or for reversing rotary motion without gears having orbital motion exclusively or essentially with continuously- meshing gears, that can be disengaged from their shafts with one or more one-way clutches as an essential feature
The present disclosure relates to materials and methods for spatial detection of nucleic acid in a tissue sample or a portion thereof. In particular, provided herein are materials and methods for detecting RNA so as to obtain spatial information about the localization, distribution or expression of genes in a tissue sample. In some embodiments, the materials and methods provided herein enable detection of gene expression in a single cell.
Methods of forming a structural color metal-dielectric-metal (MDM) component via a solution-based process are provided. First, a first metal layer is formed over a treated surface of a substrate by a first electroless deposition process. A surface of the treated substrate is contacted with a first plating bath that comprises a metal selected from the group consisting of: copper, aluminum, silver, alloys, and combinations thereof. A dielectric layer, for example, comprising silicon dioxide, is then deposited over the first metal layer by a sol-gel process. Next, the method comprises forming a second metal layer over the dielectric layer by a second electroless deposition process by contacting the dielectric layer with a second plating bath having a neutral pH and comprising a metal selected from the group consisting of: copper, aluminum, silver, alloys, and combinations thereof.
C23C 18/16 - Chemical coating by decomposition of either liquid compounds or solutions of the coating forming compounds, without leaving reaction products of surface material in the coating; Contact plating by reduction or substitution, i.e. electroless plating
C23C 18/18 - Pretreatment of the material to be coated
C23C 18/40 - Coating with copper using reducing agents
8.
ANATOMICAL AND FUNCTIONAL ASSESSMENT OF CAD USING MACHINE LEARNING
Anatomical and functional assessment of coronary artery disease (CAD) using machine learning and computational modeling techniques deploying methodologies for non-invasive Fractional Flow Reserve (FFR) quantification based on angiographically derived anatomy and hemodynamics data, relying on machine learning algorithms for image segmentation and flow assessment, and relying on accurate physics-based computational fluid dynamics (CFD) simulation for computation of the FFR.
41 - Education, entertainment, sporting and cultural services
Goods & Services
Education services, namely, providing conducting training programs for health care providers in the field of child and family development with particular attention to areas of difficulty during the perinatal period
University of Pittsburgh - Of the Commonwealth System of Higher Education (USA)
Regents of the University of Michigan (USA)
Inventor
Lucas, Peter C.
Mcallister, Linda M.
Kang, Heejae
Chen, Beibei
Maurer, Lisa
Hu, Dong
Cheng, Jing
Klei, Linda
Nikolovska-Coleska, Zaneta
Abstract
Small molecule inhibitors that block the interaction between B-cell lymphoma 10 protein (BCL10) and mucosa- associated lymphoid tissue lymphoma translocation protein 1 (MALT1), thereby inhibiting both the protease and scaffolding activities of MALT1, and MALT1- dependent downstream signaling, including IL-6 and IL-10 secretion by B-cell lymphoma cells and IL-2 transcription and secretion by Jurkat T cells.
C07C 317/26 - Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
C07D 209/38 - Oxygen atoms in positions 2 and 3, e.g. isatin
C07D 215/14 - Radicals substituted by oxygen atoms
C07D 235/14 - Radicals substituted by nitrogen atoms
C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
C07D 263/56 - Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
C07D 277/64 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
C07D 333/58 - Radicals substituted by nitrogen atoms
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules as defined within Formula I (as defined herein) which function as inhibitors of glucose-regulated protein 78 (GRP78) within cancer cells and/or immune cells, and which function as effective therapeutic agents for treating, ameliorating, and preventing various forms of cancer (e.g., pancreatic cancer), viral infections (e.g. SARS-CoV-2), and inflammatory diseases. In addition, this invention also relates to a new class of PROTACs having Formulas II, III and IV (as defined herein) which function as degraders of GRP78 within cancer and/or immune cells. Pharmaceutical compositions comprising said compounds of Formulas I, II, III, or IV are also within the scope of the present invention.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 215/28 - Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present disclosure relates to methods for assessing metabolic flux. In some aspects, the disclosure relates to methods for estimating absolute metabolic flux for a pathway of interest based upon a level of one or more metabolites and/or isotopologues thereof at a single point in time following administration of a tracer to a subject. In some embodiments, the methods described herein are performed or generated using artificial intelligence/machine-learning (AI/ML) models.
An epitaxial growth process, referred to as metal-semiconductor junction assisted epitaxy, of ultrawide bandgap aluminum gallium nitride (AlGaN) is disclosed. The epitaxy of AlGaN is performed in metal-rich (e.g., Ga-rich) conditions using plasma-assisted molecular beam epitaxy. The excess Ga layer leads to the formation of a metal-semiconductor junction during the epitaxy of magnesium (Mg)-doped AlGaN, which pins the Fermi level away from the valence band at the growth front. The Fermi level position is decoupled from Mg-dopant incorporation; that is, the surface band bending allows the formation of a nearly n-type growth front despite p-type dopant incorporation. With controlled tuning of the Fermi level by an in-situ metal-semiconductor junction during epitaxy, efficient p-type conduction can be achieved for large bandgap AlGaN.
H01L 33/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof
H01L 33/06 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a quantum effect structure or superlattice, e.g. tunnel junction within the light emitting region, e.g. quantum confinement structure or tunnel barrier
H01L 33/32 - Materials of the light emitting region containing only elements of group III and group V of the periodic system containing nitrogen
The disclosure provides a chimeric antigen receptor (CAR) polypeptide having an antigen binding domain comprising an extracellular lectin which specifically binds to glycoproteins expressed on the surface of target cells. Also provided herein are engineered lymphocytes expressing the CAR polypeptide, a nucleic acid molecule encoding the CAR polypeptide, and methods of treating cancer.
Disclosed are methods, designs and materials for extending the device operational lifetime of the phosphorescent organic light emitting devices (OLEDs) such as thermally activated delayed fluorescence (TADF) OLEDs. Applying a graded cohost or co-doped emission layer (EML) in the organic layers, both charge transport and charge balance can be precisely engineered to generate a uniform exciton/exciplex profile, preventing the early deaths due to the dense hot-excited states in the device. This invention is aimed at the short lifetime problem of the high efficient phosphorescent OLEDs and TADF OLEDs, especially in the white, blue and deep blue applications.
H10K 50/125 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers specially adapted for multicolour light emission, e.g. for emitting white light
A probe assembly and method of manufacture includes probe shanks having a bend at a hinge to conform around a core region. In some embodiments, the probe shank has multiple probe sub-units which include magnets shielded from electrodes on the probe shank. Attaching the magnetized probe sub-units and/or conforming the probe shanks around a core region can include capillary induced adherence. In some embodiments, the probe assemblies and methods of manufacture overcome challenges of a monolithic fabrication process.
The present invention relates to nanoparticles complexed with biomacromolecule agents configured for treating, preventing or ameliorating various types of disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising nanoparticles (e.g., synthetic high density lipoprotein (sHDL)) carrying biomacromolecule agents (e.g., nucleic acid, peptides, glycolipids, etc.), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings).
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
18.
THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING BILIARY TRACT CANCER USING DEVIMISTAT
The invention provides a method for treating biliary tract cancer in a patient in need thereof, comprising the step of intravenously administering to the patient a therapeutically effective amount of (i) devimistat, (ii) gemcitabine, and (iii) cisplatin, in order to treat the biliary tract cancer.
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A catalyst system for propane dehydrogenation includes a hollow fiber members packed with a Pt1Sn1/SiO2 catalyst. The hollow fiber membrane includes a separation layer coated on an interior surface of a support tube. The separation layer selectively removes H2 generated during the propane dehydrogenation reaction.
B01D 53/22 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
B01J 35/10 - Solids characterised by their surface properties or porosity
B01J 37/02 - Impregnation, coating or precipitation
C07C 5/48 - Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by dehydrogenation with a hydrogen acceptor with oxygen as an acceptor
20.
VEHICLE STATE-BASED LIGHT PROJECTION COMMUNICATION SYSTEM
A light projection system and method for use in communicating intent of an automated system to a user. The light projection system includes a light projector for projecting light onto a surface adjacent to the light projection system; and a controller for controlling the light projected by the light projector. The controller is configured to, in response to a vehicle state or a traffic state, cause the light to be projected by the light projector so that the light impinges the surface and is reflected as a displayed graphic conveying an intent based on the vehicle state or the traffic state.
B60Q 1/50 - Arrangement of optical signalling or lighting devices, the mounting or supporting thereof or circuits therefor the devices being primarily intended to indicate the vehicle, or parts thereof, or to give signals, to other traffic for indicating other intentions or conditions, e.g. request for waiting or overtaking
B60Q 1/00 - Arrangement of optical signalling or lighting devices, the mounting or supporting thereof or circuits therefor
21.
PEROXIDASE-BASED REPORTERS TO DETECT PROTEASE ACTIVITY AND PROTEIN INTERACTIONS
Provided herein are methods, compositions, reaction mixtures, kits and systems for measuring protease activities, detecting protein-protein interactions, and identifying signaling molecules that induce protein-protein interactions. In particular, provided herein are methods, compositions, reaction mixtures, kits and systems with a reporter motif comprising cleavage of acid-base coils-caged enhanced ascorbate peroxidase (APEX).
The present disclosure relates to gene panels, materials, and methods for evaluation of cancer in a subject. In particular, provided herein are synthetic scaffolds and methods of use thereof for predicting or monitoring response to an immune checkpoint inhibitor in a subject.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
An excitonic device includes a substrate and nanowires coupled to the substrate. Electrons and holes are spatially confined within an active region of each nanowire. The nanowires are operable for electroluminescent emission originating from excitons comprising bound states of electrons and holes in the active region of each nanowire.
H01L 33/20 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a particular shape, e.g. curved or truncated substrate
H01L 33/02 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies
H01L 33/18 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a particular crystal structure or orientation, e.g. polycrystalline, amorphous or porous within the light emitting region
H01L 33/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof
H01L 33/32 - Materials of the light emitting region containing only elements of group III and group V of the periodic system containing nitrogen
H01L 27/15 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including semiconductor components with at least one potential-jump barrier or surface barrier, specially adapted for light emission
B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
24.
Hybrid Camera System For Oscuring Personally Identifiable Information
Cameras provide an easy-to-deploy and information-rich datastream for a wide range of ubiquitous sensing and health monitoring applications. However, their unrestricted operation often captures personally identifiable information (PII), preventing their use in privacy-sensitive settings, such as the home, workplace, and hospitals. This disclosure proposes pairing RGB and thermal imaging to robustly detect and remove PII (e.g., an individual's face, skin color, gender, body shape, etc.,) from images before they are stored or sent off the device. A dual camera prototype includes an onboard embedded GPU capable of performing real-time privacy sanitization tasks at 8FPS at under 5 W power consumption. Results show that in the most fail safe settings the system completely removes all PII. In more permissive settings that maintain full compatibility with downstream computer vision methods, 99% of faces are successfully sanitized, facilitating privacy-preserved exercise tracking, in-home activity inferencing, and fall detection.
H04N 23/23 - Cameras or camera modules comprising electronic image sensors; Control thereof for generating image signals from infrared radiation only from thermal infrared radiation
THE BOARD OF TRUSTEES OF THE UNIVESITY OF ILLINOIS (USA)
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
Inventor
Burke, Martin, D.
Ekaputri, Stella
Brown, Samantha, Taylor
Schroeder, Nathan, Eric
Seo, Young, Ah
Abstract
Disclosed is a method of treating a disease or condition characterized by neurodegeneration via administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of hinokitiol, hinokitiol derivatives, and iron-transporting tropolones.
26.
COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASE
Provided herein are compositions and methods for treating and/or preventing inflammatory disease. In particular, provided herein are non mucin degrading bacteria and their use in treating and/or preventing inflammatory disease (e.g., GvHD).
A power conversion device may perform model-referenced power processing for multiple power nodes connected at one or more power ports. The power conversion device may include binning logic to bin the occupied ports according to their estimated condition of the occupying nodes within a pre-defined condition model for an expected population of power nodes. The binning logic then interconnects the binned ports to lite and sparse layer nodes in accordance with the occupancy and binning.
H02M 1/00 - APPARATUS FOR CONVERSION BETWEEN AC AND AC, BETWEEN AC AND DC, OR BETWEEN DC AND DC, AND FOR USE WITH MAINS OR SIMILAR POWER SUPPLY SYSTEMS; CONVERSION OF DC OR AC INPUT POWER INTO SURGE OUTPUT POWER; CONTROL OR REGULATION THEREOF - Details of apparatus for conversion
H02M 3/04 - Conversion of dc power input into dc power output without intermediate conversion into ac by static converters
G06N 3/04 - Architecture, e.g. interconnection topology
ONCOPIA THERAPEUTICS, INC. D/B/A/ PROTEOVANT THERAPEUTICS, INC. (USA)
Inventor
Wang, Shaomeng
Leng, Lingying
Tu, Wenbin
Yang, Lin
Wang, Mi
Kirchhoff, Paul
Xu, Guozhang
Li, Zhenwu
Tosovic, Jelena
Stuckey, Jeanne
Abstract
Described herein are compounds and conjugates of Formula II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as SMARCA2 or SMARCA4 inhibitors or degraders).
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
29.
COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF
ONCOPIA THERAPEUTICS, INC. d/b/a/ PROTEOVANT THERAPEUTICS, INC. (USA)
Inventor
Wang, Shaomeng
Leng, Lingying
Yang, Lin
Tu, Wenbin
Huang, Liyue
Wang, Mi
Jiang, Wei
Kirchhoff, Paul
Xu, Guozhang
Li, Zhenwu
Harikrishnan, Lalgudi
Priestley, E., Scott
Tosovic, Jelena
Stuckey, Jeanne
Abstract
Described herein are compounds of Formula II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as SMARCA2 or SMARCA4 degraders).
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
30.
METHODS, DEVICES, AND SYSTEMS FOR TREATING BONE DEFECTS
Provided herein are devices, systems, and methods of treating bone defects by wrapping thermoplastics around bone and molding thermoplastic to bone. Also provided herein are a sonotrode coupler and system used to perform the method. The technology provides devices, systems, and methods for containment of graft materials, matrices, and bone regenerative therapeutics and prevents surrounding tissue encroachment for guided bone regeneration.
Provided herein are systems and methods for identifying collateral lethal genes via metabolic fluxes and the use of such genes for the identification of, selections of, and use of therapeutic agents. Further provided herein are identified targets, such as MTHFD2, that may be regulated to treat or prevent diseases and conditions.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
The present disclosure provides methods, systems, and non-transitory computer-readable media for identifying efficient chemical synthesis processes, using molecular graph editing.
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (USA)
REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (USA)
Inventor
Boltz, Joshua
Rittmann, Bruce
Daigger, Glen
Katz, Lynn
Abstract
The present invention relates to methods for biological wastewater treatment for Se control in Se-laden wastewater. The Se contaminants in the wastewater include the Se oxyanions selenate (SeO42-) and selenite (HSeO3−), which are biochemically reduced and transformed to elemental selenium (Se0) by microorganisms through anaerobic biological reduction. The resulting Se0 is entrained in the biomass, which is further processed to enable the efficient recovery of concentrated Se0.
An optoelectronic system comprising a flexible optoelectronic device, wherein the device comprises a flexible plastic substrate, a coating comprising a glass or a polymer, positioned over the flexible plastic substrate, an anode and a cathode positioned over the coating, an organic heterojunction positioned between the anode and the cathode, comprising a donor material and an acceptor material, and an encapsulating layer comprising a glass or a polymer, positioned over the anode and the cathode. The device further comprises a roller configured to roll the flexible optoelectronic device into a stored position and a frame configured to mount the roller and the optoelectronic device.
H10K 30/30 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising bulk heterojunctions, e.g. interpenetrating networks of donor and acceptor material domains
H10K 30/82 - Transparent electrodes, e.g. indium tin oxide [ITO] electrodes
Plasmonic nanostructures function as an antenna-reactor nanostructure to focus and convert light into thermal/chemical energy, and thus have significant potential for sustainable solar water disinfection. However, the insufficient energy harvesting efficiency resulting from inconsistent nano-features linked with arrangement and scaling is a persistent challenge. An integrated optofluidic fabrication method is presented to produce a high density integrative plasmonic dimer array to enhance solar water disinfection. The plasmonic dimer array is constructed by a combined fabrication of self-assembly monolayer method and block-co-polymer lithography approaches. This combination leads to a two-dimensional hexagonal array of dimer structures consisting of 1.3 nm nanogap. The uniformity and high density of the nanogaps in the plasmonic dimer array allows strong light focusing and a rapid and highly efficient harvesting of photothermal energy at visible and near-infrared region.
H10K 30/35 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising bulk heterojunctions, e.g. interpenetrating networks of donor and acceptor material domains comprising inorganic nanostructures, e.g. CdSe nanoparticles
C02F 1/14 - Treatment of water, waste water, or sewage by heating by distillation or evaporation using solar energy
A tandem photovoltaic (PV) may include III-V semiconductors, silicon, a cathode electrode, an anode electrode, and a gold-to-gold metal bridge electrode. The semiconductors include p-typed and n-typed regions. To form a tandem PV structure, bottom and top PV cells can be independently fabricated. The bottom and the top PV cells are electrically connected by the gold-to-gold metal bridge interconnection, which is positioned between the bottom and the top PV cells. The metal bridge may be formed by cold-welding compression technique. This structure is compatible to the development of tandem PVs as well as thermophotovoltaic (TPV) cells.
H01L 31/0725 - Multiple junction or tandem solar cells
H01L 31/0735 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof adapted as photovoltaic [PV] conversion devices characterised by at least one potential-jump barrier or surface barrier the potential barriers being only of the PN heterojunction type comprising only AIIIBV compound semiconductors, e.g. GaAs/AlGaAs or InP/GaInAs solar cells
H01L 31/18 - Processes or apparatus specially adapted for the manufacture or treatment of these devices or of parts thereof
37.
PHOTOREACTOR FOR PHOTOCATALYSIS, RELATED SYSTEMS, AND RELATED METHODS
The disclosure relates to a photoreactor for performing photocatalytic reactions with a particulate photocatalyst loaded in the reactor. The photoreactor includes an internal wall having an outer surface and defining an interior volume, and a transparent external wall having an outer surface and an opposing inner surface. The internal and external walls are spaced apart so that they together define a reaction volume between the walls. The photoreactor further includes an external light transmission apparatus, such as a light source and/or a light guide, positioned around the external wall and being adapted to transmit light through the external and into the reaction volume. When a particulate photocatalyst loaded in the reaction volume is irradiated by external light transmission apparatus while a reactant is flowing through the reaction volume, a photocatalytic reaction can be performed to form a desired reaction product.
B01J 19/12 - Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor employing electromagnetic waves
B01J 19/00 - Chemical, physical or physico-chemical processes in general; Their relevant apparatus
38.
METHODS, SYSTEMS, AND APPARATUSES FOR DOSE OPTIMIZATION
The United States Government as Represented by the Department of Veterans Affairs (USA)
The Regents of the University of Michigan (USA)
Inventor
Strohbehn, Garth William
Boonstra, Philip Simon
Abstract
Methods, systems and apparatuses for dose optimization is disclosed. A predetermined threshold may be assigned to a medication. Dose-responses from each subject of a plurality of subjects may be collected and evaluated so that a determination may be made regarding whether a particular dose is equal to a true minimum dose with satisfactory efficacy value.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
Provided herein is technology relating to immunoisolation of cells and tissues, including, but not exclusively, to compositions, methods, and kits for encapsulating cells and/or tissues within an immunoisolating device to protect the cells/or tissues from host immune rejection.
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61P 15/08 - Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
40.
COMPOSITIONS AND METHODS FOR OBTAINING SUSPENSION HUMAN INTESTINAL ORGANOIDS HAVING A SEROSAL MESOTHELIAL LAYER
The invention disclosed herein generally relates to methods and systems for growing, expanding and/or obtaining human intestinal organoids (HIOs) having a serosal mesothelial layer. In particular, the invention disclosed herein relates to methods and systems for culturing hindgut spheroid tissue in suspension to obtain HIOs having an organized serosal mesothelial layer that is similar to primary human intestinal serosal mesothelium.
The present disclosure relates to compositions, systems, and methods for treating cancer. In particular, the present disclosure relates to compositions, systems, and methods for targeting oncogenic, Wnt-dependent transcriptional programs in cancers, utilizing as an example adrenocortical carcinoma stratification to treat adrenocortical carcinoma and drugs which have utility for patients stratified by these means.
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
This disclosure is in the field of medicinal chemistry, and relates to a new class of small-molecules having the Formula I,
This disclosure is in the field of medicinal chemistry, and relates to a new class of small-molecules having the Formula I,
This disclosure is in the field of medicinal chemistry, and relates to a new class of small-molecules having the Formula I,
or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof, wherein the variables Ring A, X, R1a, R1b, R2, R3, R4, m, n, and p are described herein, which function as dual inhibitors of EGFR proteins and PI3K proteins. The disclosure further relates to the use of the compounds described herein as therapeutics for the treatment of diseases and conditions mediated by EGFR proteins and/or PI3K proteins, such as cancer and other diseases.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Provided herein is a biomaterial comprising a sensor system comprising a donor fluorophore linked to a target binding moiety (TBM) and an acceptor molecule linked to a TBM, wherein, when the TBM linked to the donor fluorophore and the TBM linked to the acceptor molecule binds to a target, a resonance energy transfer (RET; e.g., Forster (or Fluorescence) resonance energy transfer (FRET), bioluminescent resonance energy transfer (BRET), chemiluminescent resonance energy transfer (CRET), or a combination thereof) from the donor fluorophore to the acceptor molecule occurs and a detectable signal is produced. An medical device, e.g., an implant, comprising the presently disclosed biomaterial comprising a sensor system is further provided. Related medical devices and solid supports are furthermore provided herein. Use of the biomaterials and medical devices in methods of determining a level of expression of a gene, an RNA, or a protein, is additionally provided.
Provided herein are compositions and methods for preventing, attenuating or treating T cell mediated intestinal disorders. In particular, provided herein are methods for preventing, attenuating or treating T cell mediated intestinal disorders characterized with reduced intestinal epithelial cell (IEC) specific mitochondrial complex II component intrinsic succinate dehydrogenase A (SDHA) activity and/or expression through use of compositions comprising a therapeutic agent capable of preventing and/or hindering reduction of IEC related SDHA activity and/or expression.
The disclosure relates to microparticles and nanoparticles comprising a polymer matrix comprising an uncapped polymer and a net positively charged therapeutic agent at neutral pH. More particularly the disclosure relates to PLGA and/or PLA particles comprising an uncapped polymer for extended, controlled release of positively charged proteins or peptides at neutral pH. Methods of making the particles and administering the particles are also provided.
Systems, methods, and computer-readable medium storing instructions of using transfer machine learning for predicting drug interaction outcomes include: obtaining a trained machine learning model, obtaining genetic information of pathogens of interest, generating predicted drug interaction outcome data for drug treatments of interest using the machine learning model, and indicating the predicted drug interaction outcome data. The machine learning model may be trained by obtaining training data, classifying the training data into subsets corresponding to different actual outcomes, and generating the machine learning model using the classified subsets. The training data may include drug interaction outcome data having, for each respective pathogen of the pathogens, an outcome of drug treatments applied to the respective pathogen. The predicted drug interaction outcome data may be generated based on the genetic information of the pathogens of interest or genetic information or clinical information of living subjects having the pathogens of interest.
Provided herein are microscope surveillance systems and methods. In particular, provided herein are modular, multi-functional microscope surveillance systems and methods suitable for use in incubators and other environments.
Provided herein is technology relating to polymerization and producing polymers and particularly, but not exclusively, to methods, systems, and compositions for producing articles using three-dimensional printing and for improving control of polymerization using a polymerization photoinhibitor having fast back reaction kinetics such as hexaarylbiimidazole compounds and bridged hexaarylbiimidazole compounds.
An optical phased array device and method for manufacturing an optical phased array for the optical phased array device. The method includes: forming a base layer of a waveguide array on a base substrate, determining a waveguide pattern defining a plurality of waveguide paths, and fabricating a pattern layer of the waveguide array on top of the base layer of the waveguide array according to the determined waveguide pattern. The plurality of waveguide paths branch from a common path and terminate at a plurality of edge emitters, where the plurality of edge emitters are spaced apart from one another along a first axis that extends in the first dimension along an edge of the optical phased array. The spacing of multiple ones of the plurality of emitters along the first axis is aperiodic.
G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour
G01S 7/481 - Constructional features, e.g. arrangements of optical elements
50.
OPTICAL PHASED ARRAY DEVICE AND METHOD OF MANUFACTURE
An optical phased array device and method for manufacturing an optical phased array for the optical phased array device. The method includes: forming a base layer of a waveguide array on a base substrate, determining a waveguide pattern defining a plurality of waveguide paths, and fabricating a pattern layer of the waveguide array on top of the base layer of the waveguide array according to the determined waveguide pattern. The plurality of waveguide paths branch from a common path and terminate at a plurality of edge emitters, where the plurality of edge emitters are spaced apart from one another along a first axis that extends in the first dimension along an edge of the optical phased array. The spacing of multiple ones of the plurality of emitters along the first axis is aperiodic.
G02B 6/12 - Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
Provided herein are immobilized chiral phosphoric acids and methods of using immobilized chiral phosphoric acids as catalysts for protecting group reactions.
A computer system includes memory hardware configured to store a multitask neural network, an optimization model, a material database, material feature vector inputs, and computer-executable instructions which include training the multitask neural network with the material feature vector inputs to generate a material structural parameter output, obtaining at least one of a target optical perception parameter and a target optical response, supplying the target optical perception parameter or target optical response and at least two of the multiple material data structures of the material database to the multitask neural network to output the at least one predicted material and the predicted structural parameter distribution, processing, by the optimization model, the predicted structural parameter distribution to generate a tuned structural parameter output, and transmitting the at least one predicted material and the tuned structural parameter output to a computing device to facilitate generation of an optical structure.
G06F 30/27 - Design optimisation, verification or simulation using machine learning, e.g. artificial intelligence, neural networks, support vector machines [SVM] or training a model
This disclosure relates generally to inhibitors of MHC-I downmodulation, and methods of treating or preventing an HIV infection by administering the inhibitors to a patient in need of treatment thereof.
C07D 407/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07H 17/04 - Heterocyclic radicals containing only oxygen as ring hetero atoms
Provided herein is technology relating to preventing and treating gastrointestinal dysbiosis and particularly, but not exclusively, to compositions, methods, systems, and kits for treating and/or preventing Clostridioides difficile infection in an organism.
Improved techniques for maintaining long-term cultures of the healthy and diseased human esophagus established in 2-dimension (2D) and 3-dimension is also needed. The invention disclosed herein generally relates to methods and systems for culturing and expanding esophageal cells with a growth media comprising a rho-kinase inhibitor, a WNT-activator/agonist, EGF, an inhibitor of TGF-BETA signaling, an inhibitor of BMP signaling, and hydrocortisone.
Controlling navigation of an autonomous unmanned aerial vehicle (UAV), commonly known as a drone, involves mathematical modeling and the resulting estimations. The autonomous UAV has one or more rotors, a wind sensor, and a controller for feedforward flight control implementation, per an embodiment. One estimation is of a thrust force at the rotor(s), and another estimation is of a rotor drag force at the rotors(s). Further, the wind sensor takes wind measurements. The wind measurements, the thrust force estimation, and the rotor drag force estimation are all used by the feedforward flight control in order to control navigation of the autonomous UAV. The navigation control can more readily manage flight of the autonomous UAV amid strong crosswinds, wind gusts, heavy winds, and other severe environmental conditions.
Disclosed herein are organic photosensitive devices including at least one exciton-blocking charge carrier filter. The filters comprise a mixture of at least one wide energy gap material and at least one electron or hole conducting material. As described herein, the novel filters simultaneously block excitons and conduct the desired charge carrier (electrons or holes).
H10K 30/30 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising bulk heterojunctions, e.g. interpenetrating networks of donor and acceptor material domains
B82Y 10/00 - Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
Image guided interventions are performed in a sterile environment. A device is provided for imaging at least a part of a patient, wherein the device includes a detection apparatus having a tunnel through which or into which the patient is configured to be transported for imaging purposes. A sterile cover rolled up or folded is provided at the outside of the tunnel. A covering mechanism is capable of unrolling or unfolding the sterile cover and draping the sterile cover in the tunnel, such that the inner wall of tunnel is at least partially covered by the sterile cover.
A61B 46/10 - Surgical drapes specially adapted for instruments
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
59.
METHOD OF ACTIVATING METAL-ORGANIC FRAMEWORK WITH DIMETHYL ETHER
A method of activating a metal-organic framework material can include solvent exchanging the metal organic framework material with DME and then applying a vacuum to remove the DME and any residual solvent.
The Board of Trustees of the Leland Stanford Junior University (USA)
The Regents of the University of Michigan (USA)
Vanderbilt University (USA)
Inventor
Jaiswal, Siddhartha
Bick, Alexander
Weinstock, Joshua
Abstract
Compositions and methods are provided for the analysis and treatment of conditions relating to clonal hematopoiesis of indeterminate potential (CHIP). In some embodiments, treatment is provided to reduce the progression of CHIP, particularly to reduce the progression to hematologic malignancy and/or heart disease. In other embodiments, methods are provided for determining clonal expansion, for example as a molecular diagnostic test that enables determination of clonal growth rate from a single sample. The method for determining clonal expansion can be applied to identify factors that influence clonal expansion, including environmental, metabolic, microbiome, and genetic.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The present invention relates to systems, compositions, and methods for altering nucleic acids, such as at a single position (e.g., A/T to G/C or G/C to A/T; in a gene with disease causing SNP). In particular, the present invention relates to engineered CRISPR/Cas systems comprising: a first Cas protein (e.g., Cas5-8 or Cas11) which is optionally tethered or fused to an effector protein selected from: i) an adenine deaminase, ii) a uracil glycosylase inhibitor, or iii) an APOBEC protein; and at least one guide RNA (gRNA) configured to hybridize to a portion of a target nucleic acid sequence. In certain embodiments, the systems further comprise a second Cas protein selected from: i) Cas3, ii) a helicase-deficient Cas3; or iii) a single-strand nicking Cas endonucleases (e.g., Cas9 Nickase H840A Protein).
The present disclosure provides devices and in vitro methods of developing three-dimensional neural tube-like tissues. In some aspects, the disclosure provides devices and methods of developing three-dimensional neural tube-like tissues comprising forebrain-like, midbrain-like, hindbrain-like, and spinal cord-like tissues. In particular, provided herein microfluidic devices and methods of using the same for generating neural tube-like tissues, such as neural-tube like tissues comprising forebrain-like, midbrain-like, hind-brain-like, and spinal cord-like tissues. In some embodiments, uses of such neural tube-like tissues for research, compound screening and analysis, disease modeling, and therapeutics are provided.
C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
64.
NANOFIBROUS TISSUE ENGINEERING MATRICES WITH IMPROVED CLINICAL HANDLING PROPERTIES FOR PERIODONTAL AND CRANIOFACIAL REGENERATION AND METHODS OF MAKING THE SAME
The disclosure relates generally to a tissue engineering matrix with improved clinical handling properties, designed for periodontal and craniofacial regeneration applications and methods of manufacturing the same. In one application, these matrices are fabricated as surgical membranes which serve not only as a protective barrier but also to induce regeneration through controlled release of inductive substances, facilitate regeneration through the tissue integration, and define and maintain dimensional stability in horizontal and/or vertical defects. In another application, these matrices are fabricated as macroporous scaffolds, and the novel chemistry serves to deliver a three-dimensional environment capable of facilitating tissue ingrowth, vascularization, extracellular matrix deposition and remodeling, and tissue regeneration.
Described herein are compounds of Formula I and conjugates of Formula I′ and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
Oncopia Therapeutics, Inc. d/b/a Proteovant Therapeutics, Inc. (USA)
Inventor
Wang, Shaomeng
Chen, Zhixiang
Wu, Dimin
Acharyya, Ranjan Kumar
Xiang, Weiguo
Rej, Rohan
Bai, Longchuan
Zhang, Xuqing
Xu, Guozhang
Abstract
Described herein are compounds or conjugates of of Formulae II and I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).
C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
67.
ELECTROHYDRODYNAMIC PRINTER WITH FLUIDIC EXTRACTOR
An electrohydrodynamic printer has a fluidic extractor. A stream of liquid or carrier fluid at a different electrical potential than the printing fluid passes by an extraction opening to extract printing fluid from the extraction opening. The stream of liquid can be a continuous stream, a uniform stream of droplets, or a non-uniform stream of droplets. The extracted printing fluid can merge with the extraction fluid to be carried to a printing surface for deposition. The stream of extraction fluid can be intermittently charged to intermittently extract printing fluid such that selective portions of the stream do not extract printing fluid.
The present invention provides methods and compositions for the stimulation of immune responses and for treating or preventing allergic disease and responses and inflammatory disease and responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses that prevent or treat allergic disease by reducing allergic response. Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Techniques are provided that identify and localize on to reentrant and ectopic patterns of electrical activation in the heart wall. These patterns may correspond to atrial fibrillation, ventricular fibrillation, or other heart arrhythmia conditions. The techniques detect these patterns of electrical activity using a multi-lead an intra-cavitary catheter that, along with a controller, is able to track, over a multi-dimensional cubic space, reentrant activity and identify filaments in the heart cavity. The intra-cavitary catheter includes multiple conducting poles positioned in a configuration relative to each other and functioning as either or both sensing and active poles for measuring electrical pathways in the heart wall and over the multi-dimensional space.
Provided herein are methods for the treatment and prevention of dry macular degeneration via the pharmacologic activation of autophagy without direct inhibition of mammalian target of rapamycin (mTOR), for example by administration of flubendazole.
22 monolayer is achieved using local strain to confine as well as direct exciton transport. An unexpected and massive deviation from the Einstein relation is observed and correlated with the exciton capture by defects. Experiments at elevated exciton densities reveal that the exciton drift velocity monotonically increases with exciton density, unlike exciton mobility, due to contributions from the non-equilibrium many-body effects.
A photocatalytic device includes a substrate and an array of conductive projections supported by the substrate and extending outward from the substrate, each conductive projection of the array of conductive projections having a semiconductor composition configured for photogeneration of charge carriers. Each conductive projection of the array of conductive projections is decorated with a catalyst arrangement. The catalyst arrangement includes metal nanoparticles. The semiconductor composition is doped p-type
A wind sensor and a method of making wind flow direction and wind flow velocity estimations and predictions are set forth. The wind sensor has a spherical shell body, a multitude of pressure taps, and a multitude of pressure transducers. Size, weight, power, and cost (SWaP- C) optimizations can be effected in the design and construction of the wind sensor. An inverse mathematical model, as well as machine learning, are utilized in the wind flow direction and velocity estimations. Compared to past devices, the wind sensor and method exhibit enhanced fidelity.
G01P 5/14 - Measuring speed of fluids, e.g. of air stream; Measuring speed of bodies relative to fluids, e.g. of ship, of aircraft by measuring differences of pressure in the fluid
G01W 1/02 - Instruments for indicating weather conditions by measuring two or more variables, e.g. humidity, pressure, temperature, cloud cover or wind speed
G01W 1/10 - Devices for predicting weather conditions
Provided herein are methods and compositions for treating cancer, particularly the methods and compositions comprising a neuregulin 4 (NRG4) polypeptide.
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
Inventor
Jiang, Xiaoning
Xu, Zhen
Zhang, Bohua
Wu, Huaiyu
Kim, Jinwook
Kim, Howuk
Dayton, Paul, Alexander
Goel, Leela
Abstract
A method for sonothrombolysis mediated with contrast agents includes administering at least one contrast agent into a blood vessel of a patient. The method further includes controlling application of ultrasound energy to the at least one contrast agent within the blood vessel, wherein controlling the application of the ultrasound energy includes driving an ultrasound transducer with a signal having a first frequency component and a second frequency component different from the first frequency component.
Provided herein are devices, systems, and methods for treating kidney stones. In particular, provided herein are irrigation and pump systems for use with endoscopic (e.g., ureteroscope) devices, and related methods for use in treating kidney stones and other applications.
A61B 1/015 - Control of fluid supply or evacuation
A61M 1/00 - Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
77.
COMPOSITIONS AND METHODS FOR PREVENTING, ATTENUATING, AND TREATING MEDICAL CONDITIONS WITH sHDL NANOPARTICLES
Accordingly, the present invention relates compositions comprising synthetic HDL (sHDL) nanoparticles, methods for synthesizing such sHDL nanoparticles, as well as systems and methods utilizing such sHDL nanoparticles (e.g., in diagnostic and/or therapeutic settings). In particular, the present invention provides compositions comprising sHDL nanoparticles for purposes of preventing, attenuating, and/or treating sepsis and sepsis related disorders in a subject, conditions and symptoms caused by a viral infection (e.g., COVID-19)) in a subject, and conditions and symptoms caused by thrombosis in a subject.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/4706 - 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
78.
CROSSLINKED ION-EXCHANGE MATERIALS, RELATED METHODS, AND RELATED ARTICLES
The disclosure relates to crosslinked ion-exchange materials (IEM), related methods of making lEMs, and related articles including IEMs. The IEMs can be formed by providing a reaction solution including a charged vinyl monomer, a polyfunctional vinyl crosslinking monomer, a vinyl polymerization initiator, and water; and then performing vinyl polymerization in the reaction solution to form the IEM as a crosslinked reaction product. The reaction solution contains primarily or only water as a solvent for the vinyl monomers. The resulting crosslinked reaction product has a combination of high ionic-exchange capacity (IEC) values coupled with low water uptake and/or low water mass fraction values, which make it suitable for use in various ion-exchange applications.
in vitroin vitro, which was not observed with unmodified scaffolds. Following transplantation, β-cell viability and differentiation were improved with SA-FasL modification. A sustained increase in insulin positive cell ratio was observed with SA-FasL modified relative to unmodified scaffolds. These results demonstrate that SA-FasL-modified scaffolds can mitigate initial inflammatory response and enhance β-cell engraftment and differentiation.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
C12M 3/02 - Tissue, human, animal or plant cell, or virus culture apparatus with means providing suspensions
Light emitting nanowire devices, in accordance with aspects of the present technology, can include a short period superlattice (SPSL) region underlaying an N-polar multiple quantum well (MQW) region. The short period superlattice (SPSL) region can relax strain in the multiple quantum well (MQW) region. The nanowires can be submicron scale and characterized by red electroluminescence.
H01L 33/06 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a quantum effect structure or superlattice, e.g. tunnel junction within the light emitting region, e.g. quantum confinement structure or tunnel barrier
H01L 33/18 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a particular crystal structure or orientation, e.g. polycrystalline, amorphous or porous within the light emitting region
H01L 33/02 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies
H01L 33/32 - Materials of the light emitting region containing only elements of group III and group V of the periodic system containing nitrogen
H01L 33/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof
H01L 33/20 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a particular shape, e.g. curved or truncated substrate
B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
81.
MATERIALS AND METHODS FOR LOCALIZED DETECTION OF NUCLEIC ACIDS IN A TISSUE SAMPLE
The present disclosure relates to materials and methods for spatial detection of nucleic acid in a tissue sample or a portion thereof. In particular, provided herein are materials and methods for detecting RNA so as to obtain spatial information about the localization, distribution or expression of genes in a tissue sample. In some embodiments, the materials and methods provided herein enable detection of gene expression in a single cell.
The disclosure provides biocatalysts that halogenate complex chemical compounds in specific and predictable ways. Also disclosed are halogenated complex organic compounds. The disclosure further provides methods for the halogenation of complex chemical compounds and methods of inhibiting the contraction of smooth muscle in mammals.
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
C12P 17/18 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
83.
Designing Chemical or Genetic Perturbations using Artificial Intelligence
The following relates generally to identifying perturbations (e.g., chemical perturbations, or genetic perturbations), drug treatments, and/or protein sequences. Some embodiments include a machine learning algorithm comprising a first network that converts perturbations into real-valued vector representations of the perturbations; a second network that converts cell states into real-valued vector representations of the cell states; and a third network that maps relationships between: (i) the real-valued vector representations of the perturbations, and (ii) the real-valued vector representations of the cell states. Some embodiments use the machine learning algorithm to identify a perturbation that will cause a starting cell state to transition to a target cell state by inputting the starting cell state and the target cell state into the machine learning algorithm.
A computer includes a processor and a memory, and the memory stores instructions executable by the processor to jointly train a geometric NeRF multilayer perceptron (MLP) and a color NeRF MLP to model a scene using an occupancy grid map, camera data of the scene from a camera, and lidar data of the scene from a lidar; supervise the geometric NeRF MLP with the lidar data during the joint training; and supervise the color NeRF MLP with the camera data during the joint training. The geometric NeRF MLP is a neural radiance field modeling a geometry of the scene, and the color NeRF MLP is a neural radiance field modeling colors of the scene.
In an on-demand electric charge service, a plurality of mobile power transmitters or donors deliver electric charge to one or a plurality of compatible power receivers, or vice versa. Alternatively, a plurality of mobile power receivers or donors and a plurality of power receivers or recipients form nodes of a peer-to-peer charge service, such as in a hub-spoke or a block-chain configuration. A system and/or method for establishing a charge session in an on-demand electric charge service comprises a request processing unit for receiving a charge session request for one or a plurality of power receivers or one or a plurality of mobile power transmitters, and at least one user dataset or one provider dataset.
B60L 53/38 - Means for automatic or assisted adjustment of the relative position of charging devices and vehicles specially adapted for charging by inductive energy transfer
H02J 50/80 - Circuit arrangements or systems for wireless supply or distribution of electric power involving the exchange of data, concerning supply or distribution of electric power, between transmitting devices and receiving devices
H02J 50/40 - Circuit arrangements or systems for wireless supply or distribution of electric power using two or more transmitting or receiving devices
H02J 50/90 - Circuit arrangements or systems for wireless supply or distribution of electric power involving detection or optimisation of position, e.g. alignment
A method for fabricating an organic electronic device comprises providing a plurality of photoresist structures on a substrate, the substrate having a first electrode layer, the photoresist structures having a bottom surface attached to the substrate and a top surface opposite the bottom surface, the top surface having a dimension greater than a dimension of the bottom surface, positioning a mask over the structures, the mask having a plurality of openings, and depositing an emissive material over the substrate through at least one of the plurality of openings to form at least one emissive element. An organic electronic device and a method of fabricating an organic electronic component are also described.
Provided herein are compositions and methods for the treatment of cancer by activating the spindle assembly checkpoint (SAC) in cells. In particular, dimerized Mps1 and Spc105/KNL1 constructs are provided as tunable activators of SAC, allowing for control of chromosome segregation accuracy and prevention of aneuploidies that are common in cancer.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
The disclosure is directed to compositions and methods for inhibiting an allergic reaction to two or more food allergens. The compositions comprise a nanoemulsion and at least one of the two or more food allergens.
The present disclosure provides means such as uses, nanoparticles, solutions, methods, kits and systems for screening target proteins for self-association properties (viscosity and opalescence) in ultra-dilute solutions. They provide means for screening a large number of target proteins at orders of magnitude lower concentrations than end-use formulations.
The present disclosure relates to labeling of proteins for evaluating changes in microtubule structure. Included are compositions and methods that permit detection of shortening and/or lengthening of microtubules for research, diagnostic, and therapeutic purposes.
The disclosure relates to GRAIL-1 peptide products and methods to target mutant p53 for treating p53-mutant related disease conditions such as Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC). The disclosure also relates to methods to monitor the therapeutic response of treated BE and EAC patients by detecting expression of epidermal growth factor receptor (EGER) on BE and EAC cells.
C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
The disclosure is directed to a monoclonal antibody. or an antigen-binding fragment thereof. directed against fibrils of amyloid beta (Aβ) peptides, as well as a method of treating and diagnosing neurodegenerative diseases using the monoclonal antibody.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
93.
ANALYTE DETECTION USING FLUOROGENIC PROBES OR MULTIPLEX TECHNOLOGIES
Provided herein is technology relating to detecting analytes and particularly, but not exclusively, to methods, compositions, systems, and kits for detecting analytes using fluorogenic probes and multiplex technologies.
G01N 33/542 - Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
G01N 33/557 - Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
Apparatus and methods are provided for applying ultrasound pulses into tissue or a medium in which the peak negative pressure (P−) of one or more negative half cycle(s) of the ultrasound pulses exceed(s) an intrinsic threshold of the tissue or medium, to directly form a dense bubble cloud in the tissue or medium without shock-scattering. In one embodiment, a microtripsy method of Histotripsy therapy comprises delivering an ultrasound pulse from an ultrasound therapy transducer into tissue, the ultrasound pulse having at least a portion of a peak negative pressure half-cycle that exceeds an intrinsic threshold in the tissue to produce a bubble cloud of at least one bubble in the tissue, and generating a lesion in the tissue with the bubble cloud. The intrinsic threshold can vary depending on the type of tissue to be treated. In some embodiments, the intrinsic threshold in tissue can range from 15-30 MPa.
Provided herein are methods, compositions, kits and systems for the detection, identification and quantification of bacteria and fungi. In particular, provided herein are methods, compositions, kits and systems comprising oligonucleotide primers that hybridize to sequence regions of nucleic acids flanking ribosomal 16S, 23S, 5S, 18S, 5.8S, and 25-28S internal transcribed spacer regions (ITSs) and other conserved genes from 2 or more different bacteria or fungi, polymerase chain reaction (PCR or qPCR) amplification, high resolution melt curve analysis and amplicon size determination for microbial identification.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
A method of joining a metal part and a polymer/polymer composite part comprising providing a metal part; providing a polymer or polymer composite part; inserting an insert layer between the metal part and the polymer or polymer composite part; and applying heat to the metal part to a temperature above the melting temperatures and below a degradation temperature of the polymer or polymer composite part and the insert layer and simultaneously applying pressure to the combination of the metal part, the polymer or polymer composite part, and the insert layer to combine the metal part and the polymer or polymer composite part into a joined assembly having a chemical bond therebetween.
B32B 37/04 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the partial melting of at least one layer
B32B 37/10 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the pressing technique, e.g. using direct action of vacuum or fluid pressure
B32B 37/06 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the heating method
B32B 15/08 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin
97.
Methods To Directly Join Metals To Polymer/Polymer Composites Using Functionally Active Insert Layer
A method of joining a metal part and a polymer/polymer composite part comprising providing a metal part; providing a polymer or polymer composite part; inserting an insert layer between the metal part and the polymer or polymer composite part; and applying heat to the metal part to a temperature above the melting temperatures and below a degradation temperature of the polymer or polymer composite part and the insert layer and simultaneously applying pressure to the combination of the metal part, the polymer or polymer composite part, and the insert layer to combine the metal part and the polymer or polymer composite part into a joined assembly having a chemical bond therebetween.
B32B 15/08 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin
B32B 37/06 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the heating method
B32B 37/10 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the pressing technique, e.g. using direct action of vacuum or fluid pressure
The present disclosure provides polypeptides having xanthan gum hydrolytic activity, compositions, and uses thereof. The present disclosure also provides, polynucleotides, expression vectors, host cells, and genetically modified bacteria encoding xanthanases or xanthan-utilizing gene loci.
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (USA)
REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
Inventor
Boltz, Joshua
Rittmann, Bruce
Daigger, Glen
Abstract
A biofilm membrane bioreactor system with a bioreactor, at least two membrane plates positioned within the bioreactor, and a plurality of biofilm carriers suspended within the wastewater in the bioreactor. The bioreactor has at least one inlet and at least one outlet. The at least two membrane plates are configured to filter the wastewater to generate permeate and may be formed of a ceramic material. Each of the at least two membrane plates are separated from adjacent membrane plates by a membrane gap that is at least two times larger than a smallest dimension of one of the biofilm carriers.
A method of joining a metal part and a polymer/polymer composite part comprising providing a metal part; providing a polymer or polymer composite part; inserting an insert layer between the metal part and the polymer or polymer composite part; and applying heat to the metal part to a temperature above the melting temperatures and below a degradation temperature of the polymer or polymer composite part and the insert layer and simultaneously applying pressure to the combination of the metal part, the polymer or polymer composite part, and the insert layer to combine the metal part and the polymer or polymer composite part into a joined assembly having a chemical bond therebetween.
